ISDA: 4PS5

Deposition Date 2014-03-06

Release Date 2014-03-19

Last Version Date 2023-09-20

Entry Detail

PDB ID:

4PS5

Keywords:

TRANSCRIPTION/TRANSCRIPTION INHIBITOR

Title:

Crystal structure of the first bromodomain of human BRD4 in complex with TG101348

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.40 Å

R-Value Free:

0.17

R-Value Work:

0.15

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A, B
Chain Length:127
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

2TA

ACT

EDO

Primary Citation

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors.

Ember, S.W, Zhu, J.Y, Olesen, S.H, Martin, M.P, Becker, A, Berndt, N, Georg, G.I, Schonbrunn, E.Show

Acs Chem.Biol. 9 1160 1171 (2014)

PMID: 24568369 DOI: 10.1021/cb500072z

Abstact

Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research. In co-crystallization screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and characterized 14 kinase inhibitors (10 distinct chemical scaffolds) as ligands of the KAc binding site. Among these, the PLK1 inhibitor BI2536 and the JAK2 inhibitor TG101209 displayed strongest inhibitory potential against BRD4 (IC50=25 nM and 130 nM, respectively) and high selectivity for BET bromodomains. Comparative structural analysis revealed markedly different binding modes of kinase hinge-binding scaffolds in the KAc binding site, suggesting that BET proteins are potential off-targets of diverse kinase inhibitors. Combined, these findings provide a new structural framework for the rational design of next-generation BET-selective and dual-activity BET-kinase inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form